Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 9NIH 3NETWORK 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Other hematologic neoplasm 1

Conditions

Meningioma 2Brain Neoplasms 1

Interventions

Radiotherapy 58Temozolomide 37Vincristine 33Cyclophosphamide 31Etoposide 25Carboplatin 25Filgrastim 23Cisplatin 22Granulocyte Colony-Stimulating Factor 18Lomustine 14Doxorubicin 13Chemotherapy, Adjuvant 13Peripheral Blood Stem Cell Transplantation 12Magnetic Resonance Spectroscopy 12Topotecan 11Radiation 11Isotretinoin 11Platinum 10sargramostim 9Specimen Handling 9Radiotherapy, Conformal 9Irinotecan 9Carmustine 91,2-diaminocyclohexaneplatinum II citrate 9etoposide phosphate 8Thiotepa 8Radiotherapy, Intensity-Modulated 8Radiosurgery 8Melphalan 8Immunohistochemistry 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × Hydroxyurea × CNS × Clear all
NCT06326190 2025-09-16

LUMEN-1

European Organisation for Research and Treatment of Cancer - EORTC

Phase 2 Recruiting
136 enrolled
CNS

Meningioma

NCT00003590 2016-05-20

S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma

SWOG Cancer Research Network

Phase 2 Completed
29 enrolled 5 charts
CNS

Brain Neoplasms, Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡